Kairos Pharma Files 8-K: Material Agreement & Shareholder Vote
Ticker: KAPA · Form: 8-K · Filed: Jun 12, 2025 · CIK: 1962011
| Field | Detail |
|---|---|
| Company | Kairos Pharma, LTD. (KAPA) |
| Form Type | 8-K |
| Filed Date | Jun 12, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, shareholder-vote, financials
TL;DR
Kairos Pharma (KRP) filed an 8-K on 6/10/25 covering a material agreement and shareholder vote.
AI Summary
On June 10, 2025, Kairos Pharma, Ltd. filed an 8-K report detailing a material definitive agreement, the submission of matters to a vote of security holders, and financial statements and exhibits. The company, incorporated in Delaware with its principal executive offices in Los Angeles, CA, operates in the Pharmaceutical Preparations industry.
Why It Matters
This filing indicates significant corporate actions, including a new material agreement and shareholder decisions, which could impact the company's strategic direction and financial performance.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and shareholder votes, which can introduce significant strategic and financial risks or opportunities.
Key Numbers
- 001-42275 — SEC File Number (Identifies the company's filing history with the SEC.)
- 46-2993314 — IRS Employer Identification No. (Tax identification number for the company.)
Key Players & Entities
- Kairos Pharma, LTD. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- 2355 Westwood Blvd. , #139 Los Angeles CA 90064 (address) — Principal executive offices
- June 10, 2025 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by Kairos Pharma, Ltd.?
The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the provided text.
What matters were submitted to a vote of security holders?
The filing states that matters were submitted to a vote of security holders, but the specific proposals are not detailed in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on June 10, 2025.
Where are Kairos Pharma, Ltd.'s principal executive offices located?
Kairos Pharma, Ltd.'s principal executive offices are located at 2355 Westwood Blvd., #139, Los Angeles, CA 90064.
What is Kairos Pharma, Ltd.'s Standard Industrial Classification (SIC) code?
Kairos Pharma, Ltd.'s SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 12, 2025 regarding Kairos Pharma, LTD. (KAPA).